Trial · NCT00174941
Results by group64
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 64
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit. | Febuxostat 40 mg QD | 50 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit. | Febuxostat 80 mg QD | 93 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit. | Febuxostat 120 mg QD | 65 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit. | Total Febuxostat | 82 | percentage of subjects | ||
| Percent Change in Serum Urate Levels From Baseline at Month 6 Visit. | Febuxostat 40 mg QD | -35.9 | Standard Deviation 9.55 | percent change from baseline | |
| Percent Change in Serum Urate Levels From Baseline at Month 6 Visit. | Febuxostat 80 mg QD | -50.6 | Standard Deviation 9.84 | percent change from baseline | |
| Percent Change in Serum Urate Levels From Baseline at Month 6 Visit. | Febuxostat 120 mg QD | -47.6 | Standard Deviation 19.6 | percent change from baseline | |
| Percent Change in Serum Urate Levels From Baseline at Month 6 Visit. | Total Febuxostat | -48.3 | Standard Deviation 13.07 | percent change from baseline | |
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit. | Febuxostat 40 mg QD | 57 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit. | Febuxostat 80 mg QD | 85 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit. | Febuxostat 120 mg QD | 67 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit. | Total Febuxostat | 79 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit. | Febuxostat 40 mg QD | 50 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit. | Febuxostat 80 mg QD | 82 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit. | Febuxostat 120 mg QD | 57 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit. | Total Febuxostat | 74 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit. | Febuxostat 40 mg QD | 63 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit. | Febuxostat 80 mg QD | 76 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit. | Febuxostat 120 mg QD | 92 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit. | Total Febuxostat | 77 | percentage of subjects |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00174941/results